{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0010920\nAge: 76\nGender: Male\nSample ID: P-0010920-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Prostate Adenocarcinoma\nSample Type: Primary\nTumor Purity: 60.0%\n=============\nDNA Variants:\nPALB2 c.2453T>C (p.F818S) - in 6.00% of 246 reads\nCNA Data:\nTMPRSS2 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Prostate Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": \"Deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation in PALB2\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}"
}